Is retatrutide available for purchase?

Retatrutide is not FDA-approved and is only officially available through Eli Lilly's Phase 3 clinical trials. Research chemical vendors sell products labeled as retatrutide, but these are not verified by regulatory agencies for identity, purity, or safety. Quality varies significantly between suppliers.

What weight loss do community members report with retatrutide?

Community reports from users of research-grade retatrutide describe weight loss roughly consistent with Phase 2 clinical data (up to 24% at 48 weeks with 12 mg). However, these reports cannot be verified, product authenticity is uncertain, and selection bias in reporting should be considered.

How does community retatrutide compare to semaglutide or tirzepatide?

Community members who have used multiple GLP-1 agents frequently describe retatrutide as producing the most profound appetite suppression and weight loss. The added glucagon receptor activity is cited as providing additional energy expenditure. However, the investigational status and unverified product quality make comparisons unreliable.

What are the main risks of community retatrutide use?

The primary risks include using an unapproved investigational drug without medical supervision, uncertain product quality and identity from research chemical vendors, lack of regular safety monitoring (particularly for glucagon-related metabolic effects), and no established long-term safety data. The triple agonist mechanism creates unique pharmacological effects that may require monitoring not available outside clinical settings.

Retatrutide: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Structured Community DataBased on 100 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•3 community protocols documented
•Evidence level: Structured Community Data
•Based on 100 community reports
•1 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Availability and Source	Retatrutide is only available through Eli Lilly-sponsored Phase 3 clinical trials. No FDA-approved formulation exists.	Community members obtain retatrutide from research chemical vendors and gray-market peptide suppliers. Product quality, purity, and actual identity vary significantly between sources.	high Retatrutide purchased from research chemical suppliers has not been verified for identity, purity, or sterility by regulatory agencies. Third-party testing is the primary quality indicator relied upon by the community, but testing scope and reliability vary.
Dosing Protocol	Phase 2 trial used structured escalation from 1 mg weekly, with dose groups reaching 4, 8, or 12 mg over defined schedules. Dosing was supervised with regular clinical monitoring.	Community members attempt to replicate clinical escalation schedules but without medical supervision, regular lab monitoring, or adverse event reporting infrastructure. Some modify escalation based on personal tolerance.	high Self-administration of an investigational compound without medical monitoring carries significant risk. Clinical trial participants had regular safety assessments that community users lack.
Safety Monitoring	Clinical trials include regular vital signs, lab work, ECG monitoring, and systematic adverse event collection at predefined intervals.	Most community users rely on subjective assessment of side effects without regular blood work or clinical monitoring. Some obtain periodic lab panels independently.	high The glucagon receptor agonism in retatrutide has unique metabolic effects (hepatic glucose output, lipid metabolism) that warrant monitoring not typically available to community users.

Compare these community approaches with published research findings.

Community Protocols

Clinical Trial Escalation Protocol

Popular

Route: Subcutaneous
Dose: 1-12 mg
Frequency: Once weekly
Duration: 48+ weeks

Based on Phase 2 trial schedule: 1 mg x4 weeks, 2 mg x4 weeks, 4 mg x4 weeks, escalating up to 8 or 12 mg; community users attempt to replicate clinical dosing

Conservative Start Protocol

Common

Route: Subcutaneous
Dose: 0.5-4 mg
Frequency: Once weekly
Duration: 12-24 weeks

Some community members start at sub-clinical doses (0.5 mg) and escalate more slowly than clinical protocols to assess individual tolerance

Moderate Dose Maintenance

Common

Route: Subcutaneous
Dose: 4-8 mg
Frequency: Once weekly
Duration: Ongoing

Users report significant weight loss and appetite suppression at 4-8 mg without needing to reach 12 mg; lower doses may reduce GI and other side effects

Stacking Patterns

Retatrutide Standalone

Popular

Most community reports describe retatrutide used as a standalone compound given its triple receptor activity; stacking with other GLP-1 agonists is generally avoided

retatrutide

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 100+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

Reddit r/Peptides|Retatrutide community experiences and protocol discussions(accessed 2026-02-16)
Reddit r/Peptides|Retatrutide search results and user reports(accessed 2026-02-16)
BodySpec|Retatrutide Dosage Guide and Titration Schedule 2025(accessed 2026-02-16)
IAPAM|Retatrutide Dosage - A Guide(accessed 2026-02-16)
Swolverine|Retatrutide Dosing - What We Know So Far(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for Retatrutide (LY3437943). The information below is gathered from Reddit r/Peptides, research chemical communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.

Retatrutide has generated significant community interest following its Phase 2 trial results showing up to 24.2% weight loss at 48 weeks, the highest reported for any anti-obesity agent at the time of publication. As an investigational compound not yet FDA-approved, all community use involves research-grade material from unregulated sources.

Critical Safety Context#

Retatrutide is an investigational drug currently in Phase 3 clinical trials. It is not FDA-approved for any indication. Community use involves products from research chemical suppliers that have not been verified by regulatory agencies. Users assume significant risks including uncertain product identity and purity, unknown long-term safety, and lack of medical monitoring for a pharmacologically complex triple-receptor agonist.

Understanding Protocol Divergence#

Source and Quality Concerns#

The most critical divergence between clinical and community use is product source. Clinical trial participants receive pharmaceutical-grade retatrutide manufactured by Eli Lilly under GMP conditions. Community users obtain products from research chemical vendors with variable quality control. Third-party certificates of analysis (COAs) are the primary quality indicator, but their reliability and scope vary.

Monitoring Gap#

Clinical trial participants undergo regular safety monitoring including blood work, ECG, and clinical assessments. The glucagon receptor agonism component of retatrutide has metabolic effects (hepatic glucose output, lipid metabolism changes) that warrant monitoring not typically available to community users self-administering the compound.

Commonly Reported Outcomes#

Community members who report using research-grade retatrutide describe:

Appetite suppression: Frequently described as more pronounced than semaglutide or tirzepatide
Weight loss: Reports consistent with Phase 2 data in magnitude, though product authenticity cannot be verified
GI side effects: Nausea, diarrhea, and decreased appetite are commonly reported during escalation
Energy expenditure: Some users report feeling warmer or having increased basal metabolic rate, potentially attributable to the glucagon receptor component
Heart rate changes: Elevated resting heart rate reported by some users, consistent with clinical trial observations

Important Caveats#

Retatrutide is investigational and not FDA-approved
Products from research chemical vendors are unverified
No long-term safety data exists beyond Phase 2 trial duration
Community self-administration without medical monitoring carries significant risk
Reports should be interpreted with extreme caution given product quality uncertainty

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.